Results 91 to 100 of about 29,485 (183)
Revista da Sociedade Brasileira de Medicina Tropical, 2003 Para cada doador de sangue soropositivo (ELISA, Abbott®) para HTLV-I/II, de dezembro de 1998 a março de 2001, também foram selecionados dois soronegativos. As amostras séricas foram re-testadas pelo ELISA (Murex®) e aquelas que permaneceram soropositivas
Denise Duizit Colin +4 more
doaj
The clinical features of HTLV-I infection. HTLV-I associated myelopathy.
Uirusu, 1992 Nakagawa, Masanori +3 more
openaire +3 more sources
HTLV-I/II and blood donors: determinants associated with seropositivity in a low risk population
Revista de Saúde Pública, 2003 OBJECTIVE: Blood donors in Brazil have been routinely screened for HTLV-I/II since 1993. A study was performed to estimate the prevalence of HTLV-I/II infection in a low risk population and to better understand determinants associated with seropositivity.
Soares Bernadette Catalan +2 more
doaj
Uirusu, 2007 Human T-cell leukemia virus type I (HTLV-I) is a causative virus of adult T-cell leukemia (ATL). ATL is a highly aggressive neoplastic disease of CD4 positive T lymphocyte, which is featured by the pleomorphic tumor cells with hypersegmented nuclei, called " flower cell".
Jun-ichirou, Yasunaga, Masao, Matsuoka
openaire +1 more source
HTLV-I Basic Leucine Zipper Factor (sHBZ) Actively Associates with Nucleophosmin (B23) in the Nucleolus. [PDF]
VirusesMoghadam N, Xiao Y, Dragon F, Barbeau B.
europepmc +1 more source
A novel hybrid method with convergence analysis for approximation of HTLV-I dynamics model. [PDF]
Sci RepMolavi-Arabshahi M +2 more
europepmc +1 more source
Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples. [PDF]
J Clin Lab Anal, 2019 Yun SG, Kim SW, Sohn JY, Cho Y.
europepmc +1 more source
The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7. [PDF]
J VirolBellon M, Yeh C-h, Bai XT, Nicot C.
europepmc +1 more source